Safety and efficacy of entecavir for the treatment of chronic hepatitis B

References

• LavanchyDHepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measuresJ Viral Hepat20041129710714996343
   PubMed Web of Science ®Google Scholar
• HyamsKCRisks of chronicity following acute hepatitis B virus infection: a reviewClin Infect Dis199520499210007795104
   PubMed Web of Science ®Google Scholar
• YimHJLokASNatural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005Hepatology2006432 Suppl 1S173S18116447285
   PubMed Web of Science ®Google Scholar
• HadziyannisSJPapatheodoridisGVHepatitis B e antigen-negative chronic hepatitis B: natural history and treatmentSemin Liver Dis200626213014116673291
   PubMed Web of Science ®Google Scholar
• CarmanWFJacynaMRHadziyannisSMutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infectionLancet1989286635885912570285
   PubMed Web of Science ®Google Scholar
• HoofnagleJHDooELiangTJManagement of hepatitis B: summary of a clinical research workshopHepatology20074541056107517393513
   PubMed Web of Science ®Google Scholar
• Baraclude Package InsertWallingford, CTBristol-Myers Squibb http://packageinserts.bms.com/pi/pi_baraclude.pdf. Accessed December 4, 2010.
   Google Scholar
• YamanakaGWilsonTInnaimoSMetabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virusAntimicrob Agents Chemother19994311901939869593
   PubMed Web of Science ®Google Scholar
• SeiferMHamatakeRKColonnoRJStandringDNIn vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavirAntimicrob Agents Chemother19984212320032089835515
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGHadziyannisSJA dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patientsGastroenterology200512941198120916230074
   PubMed Web of Science ®Google Scholar
• De ManRAWoltersLMNevensFSafety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infectionHepatology200134357858211526545
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGde ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137
   PubMed Web of Science ®Google Scholar
• LaiCLShouvalDLokASEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med2006354101011102016525138
   PubMed Web of Science ®Google Scholar
• YaoGChenCLuWEfficacy and safety of entecavir compared to lamivudine in nucleoside-naive patients with chronic hepatitis B: a randomized double-blind trial in ChinaHepatol Int20071336537219669331
   PubMed Web of Science ®Google Scholar
• LeungNPengCYHannHWEarly hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovirHepatology2009491727919065670
   PubMed Web of Science ®Google Scholar
• GishRGLokASChangTTEntecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis BGastroenterology200713351437144417983800
   PubMed Web of Science ®Google Scholar
• ShouvalDLaiCLChangTTRelapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapyJ Hepatol200950228929519070393
   PubMed Web of Science ®Google Scholar
• ShermanMYurdaydinCSollanoJEntecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis BGastroenterology200613072039204916762627
   PubMed Web of Science ®Google Scholar
• YaoGZhouXXuDEntecavir for the treatment of lamivudine-refractory chronic hepatitis B patients in ChinaHepatol Int20071337338119669332
   PubMed Web of Science ®Google Scholar
• SuzukiFToyodaJKatanoYEfficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patientsJ Gastroenterol Hepatol20082391320132618554238
   PubMed Web of Science ®Google Scholar
• ShermanMYurdaydinCSimsekHEntecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeksHepatology20084819910818537189
   PubMed Web of Science ®Google Scholar
• YaoGBXuDZRenHThree years of continuous entecavir treatment in Chinese patients who had previously failed lamivudine: results from studies ETV-056 and ETV-050 (Abstract)Hepatology200848Suppl 2S267
   Web of Science ®Google Scholar
• LokASMcMahonBJChronic hepatitis B: update 2009Hepatology200950366166219714720
   PubMed Web of Science ®Google Scholar
• ChangTTLaiCLKew YoonSEntecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis BHepatology201051242243020049753
   PubMed Web of Science ®Google Scholar
• LaiCLChienRNLeungNWA one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study GroupN Engl J Med1998339261689654535
   PubMed Web of Science ®Google Scholar
• DienstagJLPerrilloRPSchiffERA preliminary trial of lamivudine for chronic hepatitis B infectionN Engl J Med199533325165716617477217
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med2003348980881612606735
   PubMed Web of Science ®Google Scholar
• ZengMMaoYYaoGA double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis BHepatology200644110811616799983
   PubMed Web of Science ®Google Scholar
• ChanHLHeathcoteEJMarcellinPTreatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trialAnn Intern Med20071471174575417909201
   PubMed Web of Science ®Google Scholar
• HouJYinYKXuDTelbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trialHepatology200847244745418080339
   PubMed Web of Science ®Google Scholar
• LaiCLGaneELiawYFTelbivudine versus lamivudine in patients with chronic hepatitis BN Engl J Med2007357252576258818094378
   PubMed Web of Science ®Google Scholar
• MarcellinPHeathcoteEJButiMTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BN Engl J Med2008359232442245519052126
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJAdefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis BN Engl J Med2003348980080712606734
   PubMed Web of Science ®Google Scholar
• LiawYFChienRNYehCTAcute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology199930256757210421670
   PubMed Web of Science ®Google Scholar
• FungSKAndreonePHanSHAdefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJ Hepatol200543693794316168522
   PubMed Web of Science ®Google Scholar
• LeungNWLaiCLChangTTExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapyHepatology20013361527153211391543
   PubMed Web of Science ®Google Scholar
• TenneyDPokornowskiKRoseREEntecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients (Abstract)Hepatology200950Suppl 2S10
   Web of Science ®Google Scholar
• TenneyDJRoseREBaldickCJLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapyHepatology20094951503151419280622
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis BN Engl J Med2005352262673268115987916
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology200613161743175117087951
   PubMed Web of Science ®Google Scholar
• Snow-LampartAKitrinosKChappellBJNo resistance to tenofovir disoproxil fumarate (TDF) detected following 192 weeks of treatment in subjects mono-infected with chronic hepatitis B virus (Abstract)Hepatology201052Suppl 1977A
   Google Scholar
• LiawYFGaneELeungN2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis BGastroenterology2009136248649519027013
   PubMed Web of Science ®Google Scholar
• TipplesGAMaMMFischerKPMutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivoHepatology19962437147178781348
   PubMed Web of Science ®Google Scholar
• AngusPVaughanRXiongSResistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymeraseGastroenterology2003125229229712891527
   PubMed Web of Science ®Google Scholar
• Borroto-EsodaKMillerMDArterburnSPooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trialsJ Hepatol200747449249817692425
   PubMed Web of Science ®Google Scholar
• TenneyDJLevineSMRoseREClinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to LamivudineAntimicrob Agents Chemother20044893498350715328117
   PubMed Web of Science ®Google Scholar
• BaldickCJEggersBJFangJHepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic responseJ Hepatol200848689590218362040
   PubMed Web of Science ®Google Scholar
• SchiffESimsekHLeeWMEfficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosisAm J Gastroenterol2008103112776278318721244
   PubMed Web of Science ®Google Scholar
• ShimJHLeeHCKimKMEfficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosisJ Hepatol201052217618220006394
   PubMed Web of Science ®Google Scholar
• LiawYFRaptopoulou-GigiMChienquerHEfficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with evidence of hepatic decompensation (Abstract)Hepatology200950Suppl 4505A
   Google Scholar
• XiZFXiaQZhangJJThe role of entecavir in preventing hepatitis B recurrence after liver transplantationJ Dig Dis200910432132719906113
   PubMed Web of Science ®Google Scholar
• PessoaMGGazzardBHuangAKEfficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapyAIDS200822141779178718753861
   PubMed Web of Science ®Google Scholar
• McMahonMAJilekBLBrennanTPThe HBV drug entecavir: effects on HIV-1 replication and resistanceN Engl J Med2007356252614262117582071
   PubMed Web of Science ®Google Scholar
• SasadeuszJAudsleyJMijchAThe anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patientsAIDS200822894795518453854
   PubMed Web of Science ®Google Scholar
• Department of Health and Human ServicesGuidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescentsOffice of AIDS Research Advisory Council (OARAC)1212009 http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. Accessed December 12, 2010.
   Google Scholar
• HammerSMEronJJJrReissPAntiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panelJAMA2008300555557018677028
   PubMed Web of Science ®Google Scholar
• McKenzieRFriedMWSallieRHepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis BN Engl J Med199533317109911057565947
   PubMed Web of Science ®Google Scholar
• BrinkmanKter HofstedeHJBurgerDMAdverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathwayAIDS19981214173517449792373
   PubMed Web of Science ®Google Scholar
• ColacinoJMMechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)Antiviral Res1996292–31251398739593
   PubMed Web of Science ®Google Scholar
• LewisWDayBJCopelandWCMitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspectiveNat Rev Drug Discov200321081282214526384
   PubMed Web of Science ®Google Scholar
• MazzuccoCEHamatakeRKColonnoRJTenneyDJEntecavir for treatment of hepatitis B virus displays no in vitro mitochondrial toxicity or DNA polymerase gamma inhibitionAntimicrob Agents Chemother200852259860518056280
   PubMed Web of Science ®Google Scholar
• LangeCMBojungaJHofmannWPSevere lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver functionHepatology20095062001200619937695
   PubMed Web of Science ®Google Scholar
• CohenSMLevyRMJovanovichJFAhnJFatal lactic acidosis associated with the use of combination oral medications to treat reactivation of hepatitis BJ Clin Gastroenterol200943101008101019461528
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis BJ Hepatol200950222724219054588
   PubMed Web of Science ®Google Scholar
• LiawYFLeungNKaoJHAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatol Int2008226328319669255
   PubMed Web of Science ®Google Scholar
• KeeffeEBDieterichDTHanSHA treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 updateClin Gastroenterol Hepatol20086121315134118845489
   PubMed Web of Science ®Google Scholar